Driven by the biology of ETS transcription factor translocations in prostate cancer (Cancer Genome Atlas Research, 2015; Chen et al., 2013; Yu et al., 2010), we introduced the oncoprotein ERG into this system and demonstrated ERG is a bonafide AR cofactor, endowed with a LXXLL-like AR interacting motif (AIM) that can reverse NTD autoinhibition through a DNA-independent association with AR’s LBD (Wasmuth et al., 2020). The gene discussed is AR; the disease is prostate cancer.